800-551-0488

Lab results are too important to go anywhere else

Beaumont Laboratory

Herpes Simplex Virus Type 1 & 2 by PCR

HSV PCR, Herpes Simplex Virus (HSV) Type 1 & 2 by PCR, HSV 1 & 2 by Detection PCR, EPIC: LAB6401, SOFT: IHSVG

Specimen Collection Criteria

Collect: ONE of the following specimen types:

  • Amniotic Fluid: 1.0 mL fluid in a sterile collection container or syringe with the needle removed. (Min: 0.5 mL) 
  • Cerebrospinal Fluid (CSF): 1.0 mL CSF in a sterile collection container. (Min: 0.5 mL)
  • Skin/Mucous Membranes: Swab the lesion and place in viral transport medium.
  • Ocular (Aqueous or Vitreous) Fluids: Submit 1.0 mL vitreous fluid (not the dilute fluid in the cassette) in a sterile collection container. (Min: 0.2 mL)
  • Vesicles: Puncture the vesicle and collect the vesicle fluid with a swab. Place the swab in viral transport medium.
  • Special Situation - Neonatal Surface Culture for HSV:
    • Culture, Virus is the preferred testing option and is mandated by the American Academy of Pediatrics. HSV by PCR should also be performed using the same specimen collected for Culture, Virus.
    • Indicate specimen source as "neonate-surface" on the requisition or in the electronic ordering system.
  • Serum: Submit a Gold-top SST tube (Min: 1.0 mL); Pediatric: submit 2 Microtainers®
  • Plasma: Submit a Lavender-top EDTA tube (Min: 1.0 mL) ; Pediatric: submit 2 Microtainers®
  • Bronchoalveolar Lavage (BAL): Submit in a sterile collection container. (Min: 0.5 mL)
  • Sputum (Expectorated, Tracheal, Trans-Tracheal, Nasotracheal, Endotracheal): Submit in a sterile collection container. (Min: 0.5 mL)
  • Tissue: Place in a sterile collection container or in Universal Transport Media (UTM, UVT)

Other specimen types require approval of the Medical Director of Molecular Pathology or Microbiology.

Physician Office/Drawsite Specimen Preparation

Do not freeze specimens. Maintain all specimen types refrigerated (2-8°C or 36-46°F) prior to transport.

Preparation for Courier Transport

Transport: All specimen types, at room temperature (20-26°C or 68-78.8°F) or refrigerated (2-8°C or 36-46°F).

Rejection Criteria

  • Frozen specimens.
  • Heparinized specimens.
  • Specimens with gross bacterial contamination.

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): 48 hours
Refrigerated (2-8°C or 36-46°F): 30 days
Frozen (-20°C/-4°F or below): Unacceptable

Specimen Storage in Department Prior to Disposal:

Refrigerated (2-8°C or 36-46°F): 7 days

Laboratory

Royal Oak Clinical Molecular Pathology Laboratory.

Performed

Sunday - Saturday.
Results available within 24 hours for CSF, ocular or pediatric specimens. Results for all other specimen types available in 2-3 days.

Reference Range

Negative.

Test Methodology

Real-Time Polymerase Chain Reaction (PCR), followed by Melting Curve Analysis.

Interpretation

A negative result does not rule out HSV infection.

Clinical Utility

This assay provides a highly sensitive and specific test for the diagnosis of Herpes Simplex Virus encephalitis and other HSV infections.

Clinical Disease

Two serotypes of Herpes Simplex Virus (HSV) have been identified: HSV-1 and HSV-2.

  • Primary HSV-1 infections usually occur after contact with infected saliva or a person with oral lesions. Most HSV-1 infections are asymptomatic. Patients with HSV-1 infections can present with gingivostomatitis, conjunctivitis, keratitis, and herpetic whitlow. Gingivostomatitis is common in children under 5 years of age and is characterized by the presence of painful vesicular lesions of the palate, buccal mucosa, pharynx, tongue and the floor of the mouth . Lesions resolve within 2 - 3 weeks after primary infection and 4 - 7 days after recurrent infection.
  • HSV-1 infections are responsible for more than 95% of Herpes Simplex Virus encephalitis cases. HSV encephalitis is the most commonly reported viral infection of the central nervous system, accounting for 10 - 20% of all viral encephalitis in the United States. Left untreated, HSV encephalitis is a vicious, often fatal neurologic infection. Epidemiologic studies indicate that HSV encephalitis may have a biphasic distribution with increased incidence of disease occurring in patients who are 5 - 30 years of age and in patients greater than 50 years of age.
  • Historically, HSV-1 had been associated with oral infections and HSV-2 had been associated with genital infections. This distinction is no longer true, 30 - 50% of genital herpes infections are caused by HSV-1 and 5 - 20% of oral infections are caused by HSV-2. HSV reactivation depends on the virus type and the anatomic site of infection.
  • Primary HSV-2 infections typically present as herpes genitalis and are characterized by extensive, bilaterally distributed papules or vesicles that merge to form large pustular or ulcerative lesions. Lesions often crust after 10 - 15 days and resolve within 2 - 4 weeks. Patients with primary infections may also present with fever, inguinal lymphadenopathy and dysuria.
  • Neonates with HSV infections have the highest incidence of visceral and CNS infections of any patient population with more than 70% of untreated cases producing disseminated or CNS infections. The mortality rate for neonatal infections is 65%. Less than 10% of neonates develop normally following HSV infection.

Epidemiology

HSV-1 infections are generally acquired during childhood. By age 60, up to 90% of the population has antibodies to HSV-1. HSV-2 infections are usually acquired after puberty and antibody prevalence rates seem to correlate with past sexual activity. Over the past ten years, HSV-1 prevalence rates have steadily declined while the prevalence rates for HSV-2 appear to be rising.

Incubation Period

The incubation period ranges from 1 - 26 days and with a mean of 6 - 8 days.

Transmission

Transmission of HSV typically occurs through close personal contact (kissing, sharing eating utensils, etc.) Or through some form of sexual contact. Virus is shed during primary infection, during episodes of recurrent herpes, and periodically in the absence of any clinically apparent disease. Asymptomatic shedding is a significant source of virus transmitted to susceptible hosts.

CPT Code

87529.

Test Codes

EPIC: LAB6401, SOFT: IHSVG

Last Updated

06/20/2017

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

This directory currently reflects information only for specimens collected and/or processed at the Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.